

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

05 Jun 2026

### Evaluation of the effect of zinc supplementation in treatment of patients with chronic pelvic pain syndrome

#### Protocol summary

Registration timing: **prospective**

#### Study aim

Evaluation of the effect of zinc supplementation in the treatment of patients with chronic pelvic pain syndrome

Last update: **2022-06-22, 1401/04/01**

Update count: **0**

#### Design

A clinical trial with the control group, phase 2-3 is performed on 60 patients with parallel groups to evaluate the effect of zinc supplementation on pelvic floor pain.

#### Registration date

2022-06-22, 1401/04/01

#### Settings and conduct

This study is performed in Shahid Beheshti Hospital. Patients with chronic pelvic pain will be treated with either a zinc supplement or a placebo, and the amount of pelvic pain before and after treatment will be compared.

#### Registrant information

##### Name

Ghasem Mohammadsharifi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3729 4005

##### Email address

mohammadsharifi.ghasem@gmail.com

#### Participants/Inclusion and exclusion criteria

Inclusion criteria: age between 18-65 years, diagnosis of chronic pelvic pain syndrome by a urologist, absence of underlying disease, free and informed written consent  
Exclusion criteria: failure to take medication regularly, drug intolerance, taking zinc supplements during the last three months, and tendency to leave during the study

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Intervention groups

Intervention group: Patients in this group, in addition to routine medications, will be treated with 30 mg of zinc supplements on a daily basis for one month. Control group: Patients in this group will receive placebo tablets daily for one month in addition to routine medications. Before the interventions, after two weeks and one month, the patients' pain and their chronic pelvic pain will be measured and compared by a questionnaire.

#### Expected recruitment start date

2022-07-22, 1401/04/31

#### Expected recruitment end date

2022-09-05, 1401/06/14

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Main outcome variables

Pain, chronic pelvic pain

#### Scientific title

Evaluation of the effect of zinc supplementation in treatment of patients with chronic pelvic pain syndrome

#### General information

#### Reason for update

#### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20210614051574N12**

Registration date: **2022-06-22, 1401/04/01**

#### Public title

Zinc supplementation and chronic pelvic pain syndrome

#### Purpose

Treatment

## **Inclusion/Exclusion criteria**

### **Inclusion criteria:**

Age between 18-65 years  
Diagnosis of chronic pelvic pain syndrome by a urologist  
Absence of underlying disease  
Free and informed written consent

### **Exclusion criteria:**

Failure to take medication regularly  
Drug intolerance  
Taking zinc supplements during the last 3 months  
Tendency to leave during the study

## **Age**

From **18 years** old to **65 years** old

## **Gender**

Both

## **Phase**

2-3

## **Groups that have been masked**

- Participant
- Care provider
- Outcome assessor

## **Sample size**

Target sample size: **60**

## **Randomization (investigator's opinion)**

Randomized

## **Randomization description**

Each participant's name and type of intervention (placebo or zinc sulfate) are written on a piece of paper and enclosed in an envelope. The envelopes containing the names of the participants will be placed in one box, and the envelopes containing the type of intervention will be placed in the other box. An uninformed person first picks up an envelope from the first box and then from the second box and gives it to the study coordinator. The coordinator writes down the participant's name and the selected intervention type. The process continues until all boxes are emptied.

## **Blinding (investigator's opinion)**

Double blinded

## **Blinding description**

This study uses a placebo similar to zinc tablets that have similar appearance properties. Patients are not aware of the type of substances they receive and are unaware of their intervention type. Also, health care providers and evaluators of the results of interventions do not know the patient groups and the type of medication received.

## **Placebo**

Used

## **Assignment**

Parallel

## **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### 1

#### **Ethics committee**

## **Name of ethics committee**

Ethics committee of Hamadan University of Medical Sciences

## **Street address**

Shahid Fahmideh St.

## **City**

Hamadan

## **Province**

Hamadan

## **Postal code**

6516719657

## **Approval date**

2022-05-06, 1401/02/16

## **Ethics committee reference number**

IR.UMSHA.REC.1401.132

## **Health conditions studied**

### 1

#### **Description of health condition studied**

Chronic pelvic pain syndrome

#### **ICD-10 code**

R10.2

#### **ICD-10 code description**

Pelvic and perineal pain

## **Primary outcomes**

### 1

#### **Description**

Pain

#### **Timepoint**

Before and after two weeks and one month after interventions

#### **Method of measurement**

Visual analog scale

### 2

#### **Description**

Chronic pelvic pain

#### **Timepoint**

Before and after two weeks and one month after interventions

#### **Method of measurement**

Chronic Prostatitis Symptom Index (NIH-CPSI)

## **Secondary outcomes**

empty

## **Intervention groups**

### 1

#### **Description**

Intervention group: Patients in this group, in addition to routine medications, treated with zinc supplements (made by Abian Company, containing 41.4 mg of zinc sulfate) will take daily intake for 1 month. Before the

interventions, after 2 weeks and 1 month, the amount of pain and chronic pelvic pain will be measured and compared by a questionnaire.

**Category**

Treatment - Drugs

**2****Description**

Control group: Patients in this group will receive placebo tablets daily for one month in addition to routine medications. Before the interventions, after two weeks and one month, the patients' pain and their chronic pelvic pain will be measured and compared by a questionnaire.

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Hamedan Shahid Beheshti Hospital

**Full name of responsible person**

Mahdi Vanaie

**Street address**

Eram Blvd.

**City**

Hamedan

**Province**

Hamadan

**Postal code**

6517953371

**Phone**

+98 913 410 8850

**Email**

mahvan13@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Reza Shokoohi

**Street address**

4th Floor, Hamedan University of Medical Sciences  
Headquarters, Shahid Fahmideh St., Pajouhesh Sq.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

8174673118

**Phone**

+98 81 3838 1970

**Email**

reza.shokohi@umsha.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Hamedan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Behruz Karkhanei

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Eram Blvd.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517953371

**Phone**

+98 81 3838 0706

**Email**

bk13472000@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Maedeh Mohseni

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Urology

**Street address**

Eram Blvd.

**City**

Hamadan  
**Province**  
Hamadan  
**Postal code**  
8174673461  
**Phone**  
+98 81 3838 0706  
**Email**  
mao\_mohseni@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Hamedan University of Medical Sciences  
**Full name of responsible person**  
Mahdi Vanaie  
**Position**  
Resident  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Urology  
**Street address**  
Eram Blvd.  
**City**  
Hamadan  
**Province**  
Hamadan  
**Postal code**  
8174673461  
**Phone**  
+98 81 3838 0706  
**Email**  
Mahdi.vanaiee@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Yes - There is a plan to make this available

### Title and more details about the data/document

All data can be shared after people have requested.

### When the data will become available and for how long

Six months after publishing the results.

### To whom data/document is available

Academic researchers

### Under which criteria data/document could be used

Scientific uses

### From where data/document is obtainable

Website of the Research Committee of Hamedan  
University of Medical Sciences

### What processes are involved for a request to access data/document

Clear request on the site to access the data by the individual and then review the request by the research assistant within 2 weeks and then allow access to the data.

### Comments